NMRA
Neumora Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$330M
5Y Perf.-87.4%
Build Your Comparison
Side-by-side financial analysisNMRA
PRAX
Try popular comparisons:
Stock Comparison
NMRA vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.70B
5Y Perf.+939.1%
NMRA vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NMRA |  PRAX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $330M | $7.70B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-222M | $-327M |
| Total Debt | $477K | $110K |
| Cash & Equiv. | $183M | $357M |
NMRA vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NMRA
PRAX
| Stock | Sep 23 | Jun 26 | Return |
|---|---|---|---|
| Neumora Therapeutic… (NMRA) | 100 | 12.6 | -87.4% |
| Praxis Precision Me… (PRAX) | 100 | 1039.1 | +939.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NMRA vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Neumora Therapeutics, Inc. Common Stock is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇PRAX emerged as the overall leader. Track its performance:
NMRA
Neumora Therapeutics, Inc. Common Stock
The Growth Play
NMRA is the clearest fit if your priority is growth exposure.
- EPS growth 5.2%
- 13.6% revenue growth vs PRAX's -100.0%
- 2.7% margin vs PRAX's 2.4%
Best for: growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Income Pick
PRAX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.55
- -36.1% 10Y total return vs NMRA's -89.0%
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  NMRA | 13.6% revenue growth vs PRAX's -100.0% |
| Quality / Margins | NMRA | 2.7% margin vs PRAX's 2.4% |
| Stability / Safety |  PRAX | Beta 1.55 vs NMRA's 1.90, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PRAX | +491.9% vs NMRA's +98.3% |
| Efficiency (ROA) | PRAX | -40.2% ROA vs NMRA's -119.2%, ROIC -65.0% vs -5.3% |
NMRA vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
NMRA vs PRAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRAXLAGGINGNMRA
NMRANeumora Therapeutics,…
1leads
PRAXPraxis Precision Medi…
3leads
6 Total Categories
CATEGORYLEADERvs NMRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NMRA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PRAX8/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX5/6
Risk & VolatilityBeta, volatility, and downside exposure
PRAX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NMRA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NMRA and PRAX operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$223M | -$357M |
| Net IncomeAfter-tax profit | -$222M | -$327M |
| Free Cash FlowCash after capex | -$193M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +28.6% | +2.7% |
NMRA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NMRA and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| Market CapShares × price | $330M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $148M | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.23x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.80x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NMRA and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PRAX leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
PRAX delivers a -43.0% return on equity — every $100 of shareholder capital generates $-43 in annual profit, vs $-182 for NMRA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NMRA's 0.00x. On the Piotroski fundamental quality scale (0–9), PRAX scores 3/9 vs NMRA's 2/9, reflecting mixed financial health.
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| ROE (TTM)Return on equity | -181.7% | -43.0% |
| ROA (TTM)Return on assets | -119.2% | -40.2% |
| ROICReturn on invested capital | -5.3% | -65.0% |
| ROCEReturn on capital employed | -108.2% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$182M | -$357M |
| Cash & Equiv.Liquid assets | $183M | $357M |
| Total DebtShort + long-term debt | $477,000 | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -47.51x | — |
PRAX leads this category, winning 8 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,580 today (with dividends reinvested), compared to $1,095 for NMRA. Over the past 12 months, PRAX leads with a +491.9% total return vs NMRA's +98.3%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs NMRA's -52.2% — a key indicator of consistent wealth creation.
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| YTD ReturnYear-to-date | +7.2% | -6.9% |
| 1-Year ReturnPast 12 months | +98.3% | +491.9% |
| 3-Year ReturnCumulative with dividends | -89.0% | +1757.4% |
| 5-Year ReturnCumulative with dividends | -89.0% | -14.2% |
| 10-Year ReturnCumulative with dividends | -89.0% | -36.1% |
| CAGR (3Y)Annualised 3-year return | -52.2% | +164.8% |
PRAX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PRAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRAX is the less volatile stock with a 1.55 beta — it tends to amplify market swings less than NMRA's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 72.7% from its 52-week high vs NMRA's 48.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.90x | 1.55x |
| 52-Week HighHighest price in past year | $3.65 | $366.52 |
| 52-Week LowLowest price in past year | $0.72 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +48.8% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 46.3 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 396K |
PRAX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates NMRA as "Buy" and PRAX as "Buy". Consensus price targets imply 293.3% upside for NMRA (target: $7) vs 127.8% for PRAX (target: $607).
| Metric | NMRANeumora Therapeut… | PRAXPraxis Precision … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $607.15 |
| # AnalystsCovering analysts | 9 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRAX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). NMRA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallPraxis Precision Medicines,… (PRAX)Leads 3 of 6 categories
Loading custom metrics...
NMRA vs PRAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NMRA or PRAX a better buy right now?
Analysts rate Neumora Therapeutics, Inc.
Common Stock (NMRA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NMRA or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -14. 2%, compared to -89. 0% for Neumora Therapeutics, Inc. Common Stock (NMRA). Over 10 years, the gap is even starker: PRAX returned -36. 1% versus NMRA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NMRA or PRAX?
By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.
(PRAX) is the lower-risk stock at 1. 55β versus Neumora Therapeutics, Inc. Common Stock's 1. 90β — meaning NMRA is approximately 22% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 0% for Neumora Therapeutics, Inc. Common Stock — giving it more financial flexibility in a downturn.
04Which is growing faster — NMRA or PRAX?
On earnings-per-share growth, the picture is similar: Neumora Therapeutics, Inc.
Common Stock grew EPS 5. 2% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NMRA or PRAX?
Neumora Therapeutics, Inc.
Common Stock (NMRA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NMRA leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — NMRA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NMRA or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NMRA or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Praxis Precision Medicines, Inc.
(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Neumora Therapeutics, Inc. Common Stock (NMRA) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRAX: -36. 1%, NMRA: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NMRA and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.